Can specially trained immune cells flush out hidden HIV?

NCT ID NCT04248192

Ongoing ⭐️ CURE ⭐️ Sponsor: Catherine Bollard Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This early-stage trial is testing whether immune cells from a donor, specially trained to attack HIV, can safely reduce the hidden HIV reservoir in people who have had a bone marrow transplant. Participants are adults with HIV who are on antiretroviral therapy and have already received a transplant. The goal is to see if these cells are safe and whether they can help the immune system clear lingering HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Donor-derived HIV-specific T-cells with non-escaped epitope targeting (DD HST-NEETs)
What this could lead to: If successful, this approach could help eliminate hidden HIV reservoirs after a bone marrow transplant, potentially leading to a functional cure for HIV.
What could go wrong: This is an early-phase trial with only 8 participants, so safety and effectiveness are not yet established. There is a risk of severe side effects, and the therapy may not reduce HIV reservoirs as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-INFECTED INDIVIDUALS

Contacts and locations

Locations

Johns Hopkins University(Jhu)

Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.